慢性丙型肝炎患者CD14+单核细胞和CD163+巨噬细胞的表达及其与肝纤维化严重程度的关系

肝脏 ›› 2024, Vol. 29 ›› Issue (4): 432-435.

慢性丙型肝炎患者CD14⁺单核细胞和CD163⁺巨噬细胞的表达及其与肝纤维化严重程度的关系

贺宇, 张志红, 欧阳慧, 鲁石

434300 湖北公安县人民医院检验科(贺宇,鲁石),肿瘤科(张志红),输血科(欧阳慧)

收稿日期:2023-12-11 出版日期:2024-04-30 发布日期:2024-08-27
通讯作者: 鲁石,Email:358646241qq.com
基金资助:
湖北省卫生健康委员会科研项目(WJ2023M177)

Expression of CD14⁺ monocytes and CD163⁺ macrophages in patients with chronic hepatitis C and their relationship with the severity of liver fibrosis

HE Yu¹, ZHANG Zhi-hong², OUYANG Hui³, LU Shi¹

1. epartment of Laboratory , Gong'an County People's Hospital Hubei 434300, China;
2. Department of Oncology ,Gong'an County People's Hospital Hubei 434300, China;
3. Department of Blood Transfusion ,Gong'an County People's Hospital Hubei 434300, China

Received:2023-12-11 Online:2024-04-30 Published:2024-08-27
Contact: LU Shi, Email: 358646241qq.com

摘要/Abstract

摘要： 目的探讨慢性丙型肝炎患者CD14⁺单核细胞和CD163⁺巨噬细胞的表达及其与肝纤维化严重程度的关系。方法选取2018年4月—2022年11月期间公安县人民医院诊治的慢性丙型肝炎患者83例,同期健康人64例,比较两组临床特征、肝组织中CD163表达、血清CD163浓度、CD14⁺细胞比例以及表达不同种类细胞因子的CD14⁺细胞比例。结果慢性丙型肝炎组(n=82)ALT水平和AST水平分别为(84.6±9.1)U/L和(69.3±7.2)U/L,显著高于健康对照组(n=64)的(28.4±1.7)U/L和(22.5±6.9)U/L(P<0.05);慢性丙型肝炎患者中F<2者CD163⁺细胞数量、血清CD163浓度和CD14⁺细胞比例分别为38.2±4.7、(73.6±2.1)μg/L和(73.7±3.2)%,显著高于健康对照组的12.5±1.3、(50.1±2.6)μg/L和(61.0±8.4)%,F≥2患者CD163⁺细胞数量、血清CD163浓度和CD14⁺细胞比例分别为74.9±8.0、(95.4±9.8)μg/L和(79.2±5.5)%,显著高于健康对照组和F<2患者。F<2慢性丙型肝炎患者表达IL-2、IL-4、IFN-γ、IL-6、IL-8和TNF-α的CD14⁺细胞比例分别为(4.2±1.2)%、(3.8±1.1)%、(3.8±1.0)%、(3.7±1.3)%、(4.0±1.4)%和(6.7±3.6)%,显著高于健康对照组的(0.9±0.1)%、(1.1±0.2)%、(1.8±0.4)%、(1.6±0.6)%、(1.7±0.7)%和(4.6±2.1)%,F≥2患者表达IL-2、IFN-γ、IL-8和TNF-α的CD14⁺细胞比例分别为(2.2±0.8)%、(2.1±0.5)%、(5.6±2.0)%和(6.9±3.2)%,显著高于健康对照组,表达IL-8的CD14⁺细胞比例为(5.6±2.0)%,显著高于F<2患者。结论 CD14⁺单核细胞和CD163⁺巨噬细胞参与了慢性丙型肝炎患者肝纤维化的进程。

关键词: 慢性丙型肝炎, 单核细胞, 巨噬细胞

Abstract: Objective To investigate the expression of CD14⁺ monocytes and CD163⁺ macrophages in patients with chronic hepatitis C and their relationship with the severity of liver fibrosis. Methods A total of 83 patients with chronic hepatitis C and 64 healthy subjects were selected between April 2018 and November 2022. The clinical features, the expression of CD163 in liver tissue, the concentration of serum CD163, the proportion of CD14⁺ cells and the proportion of CD14⁺ cells expressing different kinds of cytokines were compared. Results The level of ALT and AST of chronic hepatitis C group were (84.6±9.1) U/L and (69.3±7.2) U/L, which was significantly higher than that in healthy control group [(28.4±1.7) U/L and (22.5±6.9) U/L] (P<0.05). The concentration of serum CD163 and the proportion of CD14⁺ cells, the number of CD163⁺ cells, concentration of serum CD163⁺ and CD14⁺ cell proportion of F<2 patients were 38.2±4.7, (73.6±2.1) μg/L and (73.7±3.2) %, which was significantly higher than that in healthy control group [12.5±1.3, (50.1±2.6) ?g/L and (61.0±8.4) %] (P<0.05). The number of CD163⁺ cells, concentration of serum CD163⁺ and CD14⁺ cell proportion of F≥2 patients were 74.9±8.0, (95.4±9.8) μg/L and (79.2±5.5) %, which was significantly higher than that in healthy control group and F<2 patients. CD14⁺ cells expressing IL-2, IL-4, IFN-γ, IL-6, IL-8 and TNF-α of F<2 patients were (4.2±1.2) %, (3.8±1.1) %, (3.8±1.0) %, (3.7±1.3) %, (4.0±1.4) % and (6.7±3.6) %, which was significantly higher than that in healthy control group [(0.9±0.1) %, (1.1±0.2) %, (1.8±0.4) %, (1.6±0.6) %, (1.7±0.7) % and (4.6±2.1) %] P<0.05). CD14⁺ cells expressing IL-2, IFN-γ, IL-8 and TNF-α of F≥2 patients were (2.2±0.8) %, (2.1±0.5) %, (5.6±2.0) % and (6.9±3.2) %, which was significantly higher than that in healthy control group. CD14⁺ cells expressing IL-8 was (5.6±2.0) %, which was significantly higher than that in F≥2 patients. Conclusion CD14⁺ monocytes and CD163⁺ macrophages are involved in the process of liver fibrosis in patients with chronic hepatitis C.

Key words: Chronic hepatitis C, Monocytes, Macrophages

贺宇, 张志红, 欧阳慧, 鲁石. 慢性丙型肝炎患者CD14⁺单核细胞和CD163⁺巨噬细胞的表达及其与肝纤维化严重程度的关系[J]. 肝脏, 2024, 29(4): 432-435.

HE Yu, ZHANG Zhi-hong, OUYANG Hui, LU Shi. Expression of CD14⁺ monocytes and CD163⁺ macrophages in patients with chronic hepatitis C and their relationship with the severity of liver fibrosis[J]. Chinese Hepatolgy, 2024, 29(4): 432-435.

/ 推荐

参考文献

[1] Tsai WC, Chiang HC, Chiu YC, et al. Chronic Hepatitis C Virus Infection: An Ongoing Challenge in Screening and Treatment[J]. Life (Basel), 2023, 13(10):1964.
[2] Zakurdaeva K, Tsimafeyeu I. Immunotherapy in cancer patients with chronic hepatitis C viral infection[J]. J Cancer Res Ther, 2023, 19(5): 1093-1097.
[3] Nunes PF, da Cruz Coelho E, da Silva JR, et al. Hepatitis C and Human Pegivirus Coinfection in Patients with Chronic Hepatitis C from the Brazilian Amazon Region: Prevalence, Genotypes and Clinical Data[J]. Viruses, 2023, 15(9):1892.
[4] Zhang F, Fan L, Liu Q, et al. Comprehensive immune cell analysis of human menstrual-blood-derived stem cells therapy to concanavalin A hepatitis[J]. Front Immunol, 2022, 13: 974387.
[5] Peng B, Li H, Liu K, et al. Intrahepatic macrophage reprogramming associated with lipid metabolism in hepatitis B virus-related acute-on-chronic liver failure[J]. J Transl Med, 2023, 21(1): 419.
[6] Zhu Y, Liu Y, Ma Y, et al. Macrophage autophagy deficiency-induced CEBPB accumulation alleviates atopic dermatitis via impairing M2 polarization[J]. Cell Rep, 2023, 42(11): 113430.
[7] Li Z, Cao Z, Li N, et al. M2 Macrophage-Derived Exosomal lncRNA MIR4435-2HG Promotes Progression of Infantile Hemangiomas by Targeting HNRNPA1. Int J Nanomedicine, 2023, 18: 5943-5960.
[8] Huang X, Deng Y, Xiao J, et al. Genetically engineered M2-like macrophage-derived exosomes for P. gingivalis-suppressed cementum regeneration: From mechanism to therapy[J]. Bioact Mater, 2024, 32: 473-487.
[9] Deswal B, Bagchi U, Kapoor S. Curcumin Suppresses M2 Macrophage-derived Paclitaxel Chemoresistance through Inhibition of PI3k-AKT/STAT3 Signaling[J]. Anticancer Agents Med Chem, 2024,24(2):146-156.
[10] Edwards CL, Engel JA, De Labastida Rivera F, et al. A molecular signature for IL-10-producing Th1 cells in protozoan parasitic diseases[J]. JCI Insight, 2023,8(24):e169362.
[11] O′Neal KA, Zeltner SL, Foscue CL, et al. Bhlhe40 limits early IL-10 production from CD4(+) T cells during Plasmodium yoelii 17X infection[J]. Infect Immun, 2023: e0036723.
[12] Khan MA, Ashoor GA, Shamma T, et al. IL-10 Mediated Immunomodulation Limits Subepithelial Fibrosis and Repairs Airway Epithelium in Rejecting Airway Allografts[J]. Cells, 2021, 10(5):1248.
[13] Kurosaki F, Uchibori R, Sehara Y, et al. AAV6-Mediated IL-10 Expression in the Lung Ameliorates Bleomycin-Induced Pulmonary Fibrosis in Mice[J]. Hum Gene Ther, 2018, 29(11): 1242-1251.
[14] Hanouneh IA, Zein NN, Lopez R, et al. IL-2 Receptor Antagonist (Basiliximab) Is Associated with Rapid Fibrosis Progression in Patients with Recurrent Hepatitis C after Liver Transplantation Using Serial Biopsy Specimens[J]. Int J Organ Transplant Med, 2010, 1(1): 7-14.
[15] Maranatha D, Hasan H, Bakhtiar A, et al. Association of TNF-alpha, TGF-beta1, amphiregulin, IL-2, and EGFR WITH pulmonary fibrosis in COVID-19[J]. J Infect Public Health, 2022, 15(10): 1072-1075.